Login
$CRSP
$40.61 +$0.24 (0.59%) After hours

$CRSP SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
13 Nov 2026 SCHEDULE 13G/A
10 Nov 2026 SCHEDULE 13G
06 Nov 2026 144
06 Nov 2026 Form 4: Sakhamuri Sivakesava, Chief Technical Officer

Granted 90,000 Stock Option (Right to Buy) · Granted 40,000 Restricted Stock Units

02 Nov 2026 Form 3: Sakhamuri Sivakesava, Chief Technical Officer

No securities owned

02 Nov 2026 10-Q
02 Nov 2026 8-K: Results of Operations and Financial Condition

– CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 –

28 Oct 2026 Form 4: Silver Andrew Jacob, Chief Financial Officer

Granted 18,000 Stock Option (Right to Buy) · Granted 9,000 Restricted Stock Units

28 Oct 2026 Form 4: Kasinger James R., General Counsel and Secretary

Granted 18,000 Stock Option (Right to Buy) · Granted 9,000 Restricted Stock Units

28 Oct 2026 Form 4: Kulkarni Samarth, Director

Granted 57,500 Stock Option (Right to Buy) · Granted 28,750 Restricted Stock Units

28 Oct 2026 Form 4: Patel Naimish, Chief Medical Officer

Granted 24,000 Stock Option (Right to Buy) · Granted 12,000 Restricted Stock Units

21 Oct 2026 Form 4: Silver Andrew Jacob, Chief Financial Officer

Granted 25,000 Restricted Stock Units

21 Oct 2026 Form 3: Silver Andrew Jacob, Chief Financial Officer
20 Oct 2026 Form 4: Kulkarni Samarth, Director

Received 100,000 shares by exercise or conversion · Sold 47,837 shares ($2.38M)

19 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

This Employment Agreement (“Agreement”) is made as of the Nineteenth (19th) day of October, 2026 between CRISPR Therapeutics, Inc., a Delaware corporation (the “Company”), and Andrew J. Silver (the “Executive” and, together with the Comp...

16 Oct 2026 Form 4: George Simeon, Director

Received 30,000 shares by exercise or conversion ($420K) · Sold 14,514 shares ($720K)

15 Oct 2026 Form 4: Kasinger James R., General Counsel and Secretary

Received 2,113 shares by exercise or conversion · Sold 1,040 shares ($51.2K)

15 Oct 2026 Form 4: Kulkarni Samarth, Director

Received 8,333 shares by exercise or conversion · Sold 4,098 shares ($202K)

14 Oct 2026 144

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support